SCHEMBL22728474

SCHEMBL22728474

COc1ccnc(C(=O)Nc2nc(-c3ccc(C)cc3)cs2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.59
▸ ALDH1A1 P00352 5/20 0.59
▸ THRB P10828 1/20 0.59
▸ MEN1 O00255 5/20 0.58
▸ KMT2A Q03164 5/20 0.58
▸ NPC1 O15118 5/20 0.58
▸ RAB9A P51151 4/20 0.58
▸ MAPK1 P28482 3/20 0.58
▸ RECQL P46063 2/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ POLB P06746 3/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ ESR1 P03372 1/20 0.56
▸ ESR2 Q92731 1/20 0.56
▸ LMNA P02545 5/20 0.56
▸ SMN1; SMN2 Q16637 5/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ HTT P42858 4/20 0.55
▸ TP53 P04637 1/20 0.55
▸ CASP3 P42574 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22728560 0.87 MEN1 (0.62) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL22728480 0.85 MEN1 (0.59) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL26884349 0.84 KMT2A (0.61) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL16073046 0.82 MAPK1 (0.64) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL16078325 0.81 MEN1 (0.62) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL12248896 0.81 ADORA3 (0.68) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL12301134 0.81 ADORA3 (0.71) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL22728481 0.80 LMNA (0.64) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL22728558 0.79 MPL (0.69) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL22728498 0.79 LMNA (0.78) MAPTALDH1A1THRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2022-08-23 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2022-02-17 — — US disclosed
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2020-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 MAPT 4065/4885ALDH1A1 3368/4885THRB 1809/4885
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder TNF, MSR1, GRN MAPT 2213/4885ALDH1A1 3390/4885THRB 2801/4885
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN MAPT 2213/4885ALDH1A1 3390/4885THRB 2801/4885
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN MAPT 2213/4885ALDH1A1 3390/4885THRB 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback